Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 2h#MASLD patients with high cardiovascular risk have more severe #liverfibrosis and higher risk of liver complications, highlighting the need for integrated cardiometabolic and hepatic care. 🔗: ow.ly/13B050ZTbXX 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 30/09/2026💫 #MetALD affects women differently. From greater alcohol sensitivity to menopause-related risk and transplant disparities, this review synthesizes evidence on sex-specific biology, outcomes, and care gaps in women with MetALD. 🔗: ow.ly/3OKR50ZTbQL 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 23/09/2026📖 The October issue of CGH is now online! It features: 🟢A Narrative review on metabolic dysfunction and alcohol-associated steatotic liver disease in women. 🟢Risk Stratification of a Novel Noninvasive Fibrosis Score in MASLD 🟢And much more! 🔗: ow.ly/vqnF50ZQznw 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 18/09/2026⏰Not too late to explore the September issue! If you haven't checked it out yet, don't miss: 🟧Research on IBD and functional dyspepsia in night shift workers 🟧 A systematic review of steroid therapies for eosinophilic esophagitis 🟧 And much more! 🔗: ow.ly/YgmU50ZOlMx 001
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 16/09/2026This #PeerReviewWeek 💫 CGH recognizes Dr. Joan Genescà as one of our top reviewers! His dedication to peer review has helped ensure scientific quality while advancing clinical practice and medical knowledge. Thank you Dr. Genescà! 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 14/09/2026🩺📈 In a large #MASLD cohort, 1-year changes in liver stiffness predicted long-term liver-related events and decompensation, while CAP, ALT, and FIB-4 changes did not. Early LSM changes may be a strong marker of long-term prognosis. 🔗 ow.ly/pgTe50ZLeJw 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 11/09/2026📣Maintaining or improving healthy behaviors during early adulthood was associated with a reduction risk of midlife steatotic liver disease, regardless of genetic background. 🔗: ow.ly/AmGh50ZLezJ 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 09/09/2026🧪🌍 In 18,759 MASLD patients across 41 countries, noninvasive tests showed good accuracy but varied by age, T2D, and obesity. Agile-3+ remained consistently reliable, supporting more personalized risk stratification and testing strategies. 📊 🔗: ow.ly/BbPw50ZLept 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 04/09/2026💫 In a Veterans cohort, alcohol use disorder increased HCC risk primarily through active hepatitis C infection. Direct-acting antivirals reduced, but did not eliminate, this risk, underscoring the need for multidisciplinary AUD care. 🔗: ow.ly/lYHA50ZJ017 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 31/08/2026📖 In this study on EUS-PPG, we established expert agreement on best practices, technique and future research practices using the modified Delphi process, with total 53 consensus statements after 2 rounds of voting. 🔗: ow.ly/WZHS50ZGej7 @ThomasJWangMD 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 28/08/2026INTELCAPE: a deep learning system that automates Crohn’s disease diagnosis via capsule endoscopy. It boosts clinician accuracy by 18.2 percentage points and cuts reading time by 65.7%, especially aiding less-experienced doctors. Read more here: ow.ly/qSOj50ZGeeT 020
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 24/08/2026📖 The September issue is now online! It features: 🔷 Research on IBD and functional dyspepsia in night shift workers 🔷 A systematic review of steroid therapies for eosinophilic esophagitis 🔷 A noninvasive AI technique for diagnosing Crohn’s disease 🔗 ow.ly/eTI850ZEOki 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 21/08/2026🩺 Should all elderly patients with uncomplicated bile duct stones undergo ERCP? This study found early ERCP was not associated with better outcomes and may increase adverse events. Findings support a selective, “as-needed” approach. 📊 🔗:https://ow.ly/xAvE50ZAZJ8 001
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 19/08/2026✨Less sugar early in life may have lasting benefits. This study found a 30% lower risk of adult #MASLD and related liver complications 🩺, with over 60% of the protective effect mediated by improved metabolic traits 🔗: ow.ly/hCto50ZAWHg 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 12/08/2026🩺 JAK inhibitors are effective and safe rescue therapies for ASUC across short-, intermediate-, and long-term follow-up. Tofacitinib and Upadacitinib showed similar outcomes. 📊💊 @DrAnuraagJ @ibdseb @drvishal82 🔗: ow.ly/EVMe50ZyWya 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 29/07/2026💫 The newest issue of CGH is here! Check out this featured article ➡️ "Artificial Intelligence Tools for Gastrointestinal Research: A Practical Guide" 🔗: ow.ly/Jfzt50ZtRRh 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 20/07/2026🩺 New research shows that integrating the aMAP score with liver stiffness measurements significantly improves prediction of hepatocellular carcinoma (HCC) risk in patients with chronic hepatitis B receiving antiviral therapy. 🔗: ow.ly/MVtN50ZojoG 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 17/07/2026🧠 New in CGH! Diary-based data reveal fecal incontinence is more than urge vs passive. 💩📊 Four distinct phenotypes link stool patterns, anorectal function, and quality of life—supporting a more personalized approach to care. 🔗: ow.ly/a5Qt50ZlFvU 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 15/07/2026"Among patients with #cirrhosis, discrimination and mistrust are common, especially for Black patients. Tackling these barriers is essential for equitable liver care." X: @nicole_rich8; @docamitgs; @kanwalfasiha" 🔗: ow.ly/GoQf50ZlETG 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 13/07/2026🔬🩺 Sessile serrated lesions are key #CRC precursors but are often missed. In a multicenter randomized tandem trial, NBI significantly lowered miss rates for SSLs, proximal serrated lesions, and adenomas. 🎯 🔗: ow.ly/ZLP250ZlEIL 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 10/07/2026🌍🩺 #IBD is a global disease. In a systematic review of population-based studies including 1+ million patients, researchers found largely similar IBD phenotypes across ethnicities and regions, with notable differences observed in #Crohnsdisease. 🔬 🔗:https://ow.ly/l61V50ZlEv8 010
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 08/07/2026🩺 Early #livertransplant referral can be life-saving. This expert guidance helps providers recognize when patients with decompensated cirrhosis may benefit from transplant evaluation and specialized care. 🫀#CGH 🔗: ow.ly/ynrG50ZlCUo 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 02/07/2026🚨 ICYMI: The July issue of #CGH is now online! 🟧 Research on narrow-band imaging and sessile serrated lesion miss rates 🟧 A review offering guidance for timely liver transplantation referral 🟧 A systematic review of IBD phenotypes across race, ethnicity, and geography 🔗: ow.ly/EJ0350ZjJ2I 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 19/06/2026Can liver stiffness changes predict outcomes? 📊 This meta-analysis shows dynamic LSM shifts matter—↑ risk in progressors, ↓ risk in regressors ✅ Serial LSM could help monitor chronic liver disease & guide trials. 🧬 #LiverDisease #Hepatology 🔗: ow.ly/6UUl50ZepbB 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 18/06/2026CGH has received a 2025 Impact Factor of 16.2! On behalf of Editor-in-Chief Charles Kahi, thank you to our editors, authors, reviewers, and readers for your continued support. ow.ly/C1J950Zeox2 #GITwitter #LiverTwitter @JosephHabibi_MD @AmerGastroAssn ow.lyJust released: AGA journals receive new Impact Factor scoresThe American Gastroenterological Association (AGA) is the trusted voice of the GI community. AGA publishes top-tier journals, guidelines and patient education ... 010
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 17/06/20261 in 3 asymptomatic Barrett’s patients on PPI still show pathological reflux on 24‑hr pH monitoring—linked to neoplasia. 🧪 Esophageal function testing can guide personalized care and may help reduce progression risk. 🎯 🔗: ow.ly/i2un50ZbZ66 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 12/06/2026High cecal intubation rates (CIR) matter! 📊 An Austrian registry study shows lowest PCCRC death risk when endoscopist CIR >95%, outperforming current 90–95% standards—higher is better. ✅ @jzspitzenberg 🔗: ow.ly/3pvL50Z8TMo 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 10/06/2026Using the All of Us database, we found sexual orientation was independently linked to DGBI diagnoses in men, not women. 🧠 Gay & bisexual men had higher odds of IBS, functional diarrhea, and chronic constipation vs. straight men. 📊 🔗: ow.ly/ySYV50Z8TFb 010
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 08/06/2026This large, real-world study of Veterans with IBD using quasi-experimental study designs, vitamin D supplementation was associated with reduced emergency department visits (34% RRR), hospitalizations (53% RRR), and corticosteroid prescriptions (25% RRR). 🔗https://ow.ly/A3Ar50Z8T4X 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 01/06/2026📌Metabolic dysfunction drives MASLD risk in children. In a 4-year study, persistent or new metabolic issues increased hepatic steatosis risk—but resolution removed excess risk. Early intervention is key for improving pediatric liver health. 🔗: ow.ly/z6xf50Z4Pwq 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 29/05/2026🌟Noninvasive scores (SAVE, ABC, LSPS, CHESS-ALARM) better predict decompensation in compensated advanced chronic liver disease than fibrosis models (MELD, ALBI, VITRO, FIB‑4) in practice. 🔗: ow.ly/byff50Z4NxC 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 27/05/2026📖 The June issue of #CGH is now online! It features: 🟣 A study on the effect of CIR on Post Colonoscopy Colorectal Cancer Deaths 🟣 Research on Psychomotor Development in Infants 🟣 A 10-Year Retrospective Multicenter Survey on 997 Patients in China 🔗: ow.ly/QRjE50Z4NhH 011
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 20/05/2026Adults diagnosed with #CeliacDisease with impaired work ability face higher health care costs—not just at diagnosis, but years later, often from non‑celiac causes. New research calls for personalized, multidisciplinary care. 🔗: ow.ly/otYV50Z2cMe #CeliacAwarenessMonth 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 15/05/2026Text message 📱 and mailed reminders ✉️ significantly boosted responses to mailed FIT in a randomized trial—but a branded box didn’t move the needle. 📦❌ @PM_Innovation @PennMedicine 🔗: ow.ly/9u1z50YVzF2 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 13/05/2026📊👧 When should children be screened for #CeliacDisease? New cost-effectiveness modeling suggests a one-time screening around age 11 may be most efficient—and repeated screening may work best at ages 4 and 11. 🔗: ow.ly/EfSV50YYr3w #CeliacAwarenessMonth 011
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 11/05/2026🌐In this nationwide cohort from Sweden, both histologic inflammation (vs. histologic remission) and clinically active IBD (vs. quiescent IBD) were associated with an increased 2-year mortality risk in patients with IBD. @jiangwei_sun; @ludvigsson 🔗: ow.ly/QijX50YVzgj 011
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 08/05/2026People with MASLD and advanced fibrosis have a substantial risk of hepatocellular carcinoma in this IPD meta-analysis. Findings may inform future risk‑stratification strategies. 🧬📊 @DrHuangDQ @LimRyan21 🔗: ow.ly/rZKm50YVyPI 010
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 06/05/2026🚨Placebo response rates are often high in patients with MASH, but vary by the outcome measured. This study offers critical insights to improve future clinical trial design. 🔗: ow.ly/MymC50YVyEu 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 04/05/2026Happening soon! Join us at AGA Central for You’ve Published Your Paper… Now What? and learn strategies for promoting your work from our @AGA_GHA & @AGA_CGH social media editors Nikki Duong MD and Joseph Sleiman, MD #DDW2026 📅 5/4 | ⏰ 2 PM CT | 📍 AGA Central 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 03/05/2026Join us bright and early at AGA Central for our One Paper, Zero Confusion session — get tips on getting your title and graphical abstract just right from @AGA_CMGH editors-in-chief Michele Battle & Jonathan Katz! #DDW2026 📅 5/4 | ⏰ 8 AM CT | 📍 AGA Central 010
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 02/05/2026Happening today! Don’t miss our From Poster to Submission session at AGA Central with the editors-in-chief of @AGA_Gastro, @AGA_CGH, and @AGA_CMGH! #DDW2026 📅 5/2 | ⏰ 1 PM CT | 📍 AGA Central 010
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 01/05/2026Already published at #DDW2026? Join us at AGA Central for You’ve Published Your Paper… Now What? and learn what comes next. Featuring our @AGA_GHA & @AGA_CGH social media editors Nikki Duong MD and Joseph Sleiman, MD. 📅 5/4 | ⏰ 2 PM CT | 📍 AGA Central 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 30/04/2026Mapping out your #DDW2026 schedule? Join us at AGA Central for One Paper, Zero Confusion—tips on getting your title and graphical abstract just right with @AGA_CMGH editors-in-chief Michele Battle & Jonathan Katz! 📅 5/4 | ⏰ 8 AM CT | 📍 AGA Central 010
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 29/04/2026Attending #DDW2026? Stop by AGA Central for our From Poster to Submission session! Featuring editors-in-chief of @AGA_Gastro, @AGA_CGH, and @AGA_CMGH. 📅 5/2 | ⏰ 1 PM CT | 📍 AGA Central 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 29/04/2026📖 In case you missed it, the May 2026 issue of CGH is out! Featured topics ⬇️ 🟢 Esophageal inflammatory diseases 🟢 Extended risankizumab treatment in UC 🟢 CRC screening interventions ➡️ Full issue: ow.ly/9shw50YRMt5 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 23/04/2026There's still time! The AGA Journals are accepting applications for a one-year editorial fellowship focused on editorial training and leadership development. ⭐Perfect for early-career GIs and PhDs ✅Applications due April 30, 11:50 p.m. EST 👩⚕️Learn more: ow.ly/u7Gq50YOFoY 010
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 22/04/2026💊GLP-1 drugs like Ozempic and Wegovy have far-reaching health benefits beyond weight loss. In a new nationwide cohort study, researchers from Beth Israel Deaconess Medical Center are adding one more to that list: prevention of ulcers in the gut. 🔗: ow.ly/u2Oa50YO61B 053
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 17/04/2026🌟This international, multicenter study identified both commonalities and unique differences in disease phenotype and behavior by geography and immigrant status, highlighting the impact of changing environment on CD phenotypic expression. 🔗: ow.ly/A8uK50YLl9u 010
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 15/04/2026Subcutaneous infliximab (infliximab‑dyyb SC) maintenance improved outcomes in Crohn’s disease regardless of location, showing consistent efficacy across ileocolonic segments—including the terminal ileum. 💉✨ 🔗: ow.ly/PuPX50YFESt 000
Clinical Gastroenterology and Hepatology @aga-cgh.bsky.social · 13/04/2026🥗 Do dietary emulsifiers affect gut health? In a randomized trial, an emulsifier‑free diet lowered cholesterol, while common emulsifiers reduced short‑chain fatty acids and increased gut permeability in some participants. 🧫🦠 🔗: ow.ly/pVeC50YFEq4 000
